Analyst Recommendations for Pfizer and Peers in April



Pfizer’s performance in 2017

In 4Q17, Pfizer (PFE) reported revenues of $13.7 billion, which is a YoY (year-over-year) growth of 1%. The company reported 2017 revenues of $52.5 billion, which is a YoY decline of 1%. The company witnessed a negative top-line impact of $3 billion in 2017, of which $2.1 billion is attributable to its loss of patent exclusivity for Enbrel, Lyrica, and Vfend in developed European markets and Viagra and Pristiq in the United States.

Article continues below advertisement

Its divestiture of Hospira Infusion Systems affected the company’s sterile injectables revenues due to the shortage of legacy Hospira products in the United States. An anticipated reduction in demand for Prevnar vaccines in the adult indication in the United States and an unfavorable foreign currency fluctuation also contributed to the company’s fall in revenues in 2017.

Pfizer, however, benefited from the solid demand for Ibrance and Eliquis around the world, Inflectra in the United States and developed markets in Europe, and Xeljanz in the United States. In 2017, the company’s revenues from emerging markets rose 11%, or $1.1 billion, YoY.

Analyst recommendations for Pfizer

Of the 22 analysts covering Pfizer in April 2018, two have recommended a “strong buy,” nine have recommended a “buy,” nine have recommended a “hold,” and two have recommended a “strong sell.”

Analyst recommendations for peers

Of the 22 analysts covering Eli Lilly (LLY) in April, 59% recommend a “buy.” About 39% of the 23 analysts covering Bristol-Myers Squibb (BMY) stock recommend a “buy,” and 71% of the 21 analysts tracking Merck & Co. (MRK) recommend a “buy.”

In the next part, we’ll look at Pfizer’s revenue growth prospects for 2018.


More From Market Realist